INS and pancreatic insulinoma: Despite the availability of multimodal treatment options, including surgery, chemotherapy, embolization, radiofrequency ablation, somatostatin analogs, insulin secretion inhibitors, and mTOR or tyrosine kinase inhibitors, the prognosis of malignant insulinoma is poor and the median survival is approximately 2 years [8,9].